Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 31Rituximab 23zanubrutinib 18Vincristine 15fludarabine 14Prednisone 14venetoclax 13blinatumomab 12Specimen Handling 12Magnetic Resonance Spectroscopy 12Doxorubicin 12obinutuzumab 10Bendamustine Hydrochloride 10Lenalidomide 9Dexamethasone 8polatuzumab vedotin 7glofitamab 7Methotrexate 7Biopsy 7Radiotherapy 6Prednisolone 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Cytarabine 6pirtobrutinib 5pegaspargase 5Immunotherapy, Adoptive 5tislelizumab 4tafasitamab 4selinexor 4orelabrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Homoharringtonine × Lymphoid × Clear all
NCT07159906 2025-09-08

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

First Affiliated Hospital of Zhejiang University

Phase 1/2 Not yet recruiting
62 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡